You are leaving Medscape Education
Cancel Continue
Medscape.org provides accredited, ad-free, and evidence-based independent education
Medscape Education is a grant-funded group within the Medscape organization that maintains editorial independence to ensure unbiased educational material.
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education
 

Table 1.  

Comorbidity Potentially useful tests Management: possible treatment options
Rhinitis
- Allergic



- Nonallergic
- Associated with nasal polyps
- CRS and sinusitis
Allergy skin prick test
Serum-specific I g E



ENT examination
Sinus radiography/CT scan
Avoid relevant allergen exposure
New generation oral H, antihistamine
Intranasal corticosteroids
LTRAs
Immunotherapy
Intranasal corticosteroids
Nasal saline irrigations
Nasal anticholinergics
Oral corticosteroids
Surgical treatment
GERD Proton-pump inhibitor treatment trial
24-h esophageal measurement
Imaging techniques
Management of lifestyle
Acid-suppressive therapy
- Proton-pump inhibitor
- H2 blocker
Surgical intervention
Obesity BMI and other obesity measures
Detection of metabolic syndrome
Weight loss measures
Diet and exercise
Baryatric surgery (morbid obesity)
OSA Polysomnography
Oxymetry
CPAP plus other methods
Weight loss when relevant
Psychopathologies Psychological evaluation Psychotherapy
Referral to psychologist/psychiatrist
Dysfunctional breathing Nijmegen questionnaire [203] Psychotherapy
Breathing retraining
VCD Visualization of the pharynx
Laryngoscopy
ENT referral
Speech therapy, and so on.
Hormonal and metabolic
disorders
Hormones measurements Referral to endocrinology and metabolism specialist
Treatment of the specific disorder
COPD and smoking Pulmonary function tests
Chest radiography/CT scan
Exercise tests
Smoking cessation program
Bronchodilators
Inhaled corticosteroids
Readaptation-exercise program
Other measures and Rx
Infections
- Viral
- Bacterial
- Fungal
Specific serologies
Various identification measures
Precipitins for Aspergillus/fungal cultures/
Aspergillus serology
Specific treatment according to the agent, if available and
considered clinically significant
Systemic corticosteroids if allergic reaction to agent
(e.g., ABPA)

Assessment and management of some asthma-related comorbidities.

Provided only as examples. The reader is referred to current guidelines on this condition for further details.
ABPA: Allergic bronchopulmonary aspergillosis; COPD: Chronic obstructive pulmonary disease; CPAP: Continuous positive airway pressure; CRS: Chronic rhinosinusitis; ENT: Ear, nose and throat; GERD: Gastroesophageal reflux disease; LTRA: Leukotriene receptor antagonist; OSA: Obstructive sleep apnea; Rx: Treatment; VCD: Vocal cord dysfunction.

Box 1.  

Comorbid Conditions Commonly Associated With Asthma.

0 CME

CME

Asthma-Related Comorbidities

How does the presence of other medical conditions affect asthma severity and treatment? The current review examines this issue.
Authors: Louis-Philippe Boulet, MD; Marie-Ève Boulay, BSc
  • Authors: Louis-Philippe Boulet, MD; Marie-Ève Boulay, BSc
  • CME Released: 6/24/2011
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/24/2012, 11:59 PM EST
THIS ACTIVITY HAS EXPIRED FOR CREDIT


Target Audience and Goal Statement

This activity is intended for primary care physicians, pulmonary medicine specialists, allergists, and other physicians who care for patients with asthma.

The goal of this activity is to evaluate common conditions associated with asthma and the management of these diseases in the context of asthma.

Upon completion of this activity, participants will be able to:

  1. Analyze the relationship between upper and lower airways among patients with allergic rhinitis and asthma
  2. Evaluate the interaction between allergic rhinitis and asthma
  3. Describe the interaction of asthma, obesity, and gastroesophageal reflux disease
  4. Distinguish the effects of gender and hormonal factors on asthma


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Louis-Philippe Boulet, MD

    Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada

    Disclosure: Louis-Philippe Boulet, MD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: 3M Pharmaceuticals; ALTANA Pharma U.S.; Asthmatx, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Dynavax; Genentech, Inc.; GlaxoSmithKline; MedImmune, Inc.; Merck Frosst Canada Ltd.; Novartis Pharmaceuticals Corporation; Pharmaxis; Roche; Schering-Plough Corporation; Topigen; Wyeth Pharmaceuticals Inc.
    Received educational grants from: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Merck Frosst Canada Ltd.; Schering-Plough Corporation
    Served as an advisor for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline, Merck Frosst Canada Ltd.; Novartis Pharmaceuticals Corporation
    Served as a speaker or member of the speakers bureau for: 3M Pharmaceuticals; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Merck Frosst Canada Ltd.; Novartis Pharmaceuticals Corporation
    Louis-Philippe Boulet is a governmental adviser for the Conseil du Médicament du Québec. He is Chair of the Canadian Thoracic Society Guidelines Committee and Chair of GINA Guidelines Dissemination and Implementation Committee; holder of the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; and a member of the asthma committee of the World Allergy Organisation.

    Disclosure +
  • Marie-Ève Boulay, BSc

    Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada

    Disclosure: Marie-Ève Boulay, BSc, has disclosed no relevant financial relationships.

    Disclosure +

Editor(s)

  • Elisa Manzotti

    Editorial Director, Future Science Group, London, United Kingdom

    Disclosure: Elisa Manzotti has disclosed no relevant financial relationships.

    Disclosure +

CME Author(s)

  • Charles P. Vega, MD

    Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

    Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

    Disclosure +

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

    Disclosure +
  • Sarah Fleischman

    CME Program Manager, Medscape, LLC

    Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

    Disclosure +

Accreditation Statements

    For Physicians

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Expert Reviews Ltd. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

  • All Credits Available

        CME Released: 6/24/2011

        Valid for credit through: 6/24/2012, 11:59 PM EST

    CME

    Asthma-Related Comorbidities

    Authors: Louis-Philippe Boulet, MD; Marie-Ève Boulay, BScFaculty and Disclosures
    THIS ACTIVITY HAS EXPIRED FOR CREDIT

    CME Released: 6/24/2011

    Valid for credit through: 6/24/2012, 11:59 PM EST

    processing....

    Abstract and Introduction

    Abstract

    Asthma is often associated with various comorbidities. The most frequently reported asthma comorbid conditions include rhinitis, sinusitis, gastroesophageal reflux disease, obstructive sleep apnea, hormonal disorders and psychopathologies. These conditions may, first: share a common pathophysiological mechanism with asthma; second: influence asthma control, its phenotype and response to treatment; and third: be more prevalent in asthmatic patients but without obvious influence on this disease. For many of these, how they interact with asthma remains to be further documented, particularly for severe asthma. If considered relevant, they should, however, be treated appropriately. Further research is needed on the relationships between these conditions and asthma.

    Introduction

    Asthma is a common airway inflammatory disorder characterized by variable airway obstruction and hyperresponsiveness.[301] Asthma is of variable severity and is increasingly recognized as a condition presenting as various phenotypes.[1,2] Asthma control is the main goal of therapy and is achieved when the disease results in minimal or no symptoms, normal sleep and activities, and optimal pulmonary function.[3,4] Such control can be obtained with patient education, avoidance of environmental triggers, individualized pharmacotherapy and regular follow-up.

    Numerous comorbidities can be associated with asthma and influence its clinical expression, although their specific influence remains to be characterized. They are, however, increasingly recognized as important factors to document in asthma patients as they may influence disease management and control.

    Among the most frequently contributing comorbid conditions reported in asthmatic patients are rhinitis, sinusitis, gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), hormonal disorders and psychopathologies, although other conditions, sometimes without an evident link with asthma, have been found to be highly prevalent in asthmatic patients (Figure 1).[5,6] Indeed, analyses of large databases have shown an increased prevalence of a variety of conditions in asthmatic patients, which either influence or do not influence asthma outcomes. These large-scale analyses may, however, be biased due to contamination with, for example, patients with chronic obstructive pulmonary disease (COPD) or other conditions ( Box 1 ).

    Figure 1.

    Enlarge

    Some Common Asthma-related Comorbidities. ABPA: Allergic bronchopulmonary aspergillosis; COPD: Chronic obstructive pulmonary disease; GERD: Gastroesophageal reflux disease; OSA: Obstructive sleep apnea. Reproduced with permission from199. © European Respiratory Journal.

    In one of those reports, Prosser et al. used cross-sectional health services administrative data on treated adult asthma patients and on the general population from British Columbia (Canada), using a standardized comorbidity identification methodology, the Adjusted Clinical Group Case-Mix System.[5] Adults with asthma had significantly more comorbidities than the general population, such as respiratory infections, allergic rhinitis and high impact/high prevalence chronic conditions such as depression, found in one out of four adults with asthma. Children with asthma had a lower comorbidity burden than adults, but 12.6% had an associated chronic medical condition.

    Gershon et al. used health administrative data of 12 million residents of Ontario, Canada, in 2005, to look at comorbidities associated with asthma, as reflected by hospitalizations, emergency department visits and ambulatory care claims.[7] Asthma was associated with increased comorbidities, resulting in increased healthcare use, decreased quality of life and poor asthma control.

    Soriano et al. estimated the prevalence of comorbid diseases from an administrative data-based study including 7931 patients with asthma and matched controls.[6] The most prevalent associated condition in adult asthmatic patients was time-limited minor infections while others with a high impact and/or high prevalence were depression, hypertension, diabetes, ischemic heart disease, degenerative joint disease, cardiac arrhythmia, cancer, congestive heart failure, cerebrovascular disease and COPD. A total of 60% of adult asthma patients had at least one condition, and 12% had three or more. They also found an increased prevalence of comorbidities including various respiratory, cardiac and neurological conditions, injuries and poisonings, in individuals with asthma compared with those without asthma.[6] In both COPD and asthma, the total sum of diagnoses associated with 23 major organ systems was higher than in their matched population controls. Among incident asthma patients, the occurrence of events was generally lower than in COPD, possibly due to the younger age distribution, except for respiratory infection, but also probably due to the different impact of the disease on various systems and to the presence of common risk factors such as smoking.

    In a report by Adams et al., patients with asthma had an increased prevalence of diabetes, arthritis, heart disease, stroke, cancer and osteoporosis.[8] Van Manen et al. used a questionnaire in patients from 290 general practices over 40 years of age with asthma and/or COPD and 421 control patients.[9] Musculoskeletal conditions, insomnia, stomach and duodenal ulcers, migraine, sinusitis, depression, cancer and atherosclerosis were significantly more prevalent when patients had a diagnosis of asthma and/or COPD compared with controls. In an Australian general population health survey performed by Adams et al. on 834 adults with asthma (6609 without), arthritis, heart disease, stroke, cancer and osteoporosis were more prevalent in the presence of asthma, after age and sex adjustments.[8]

    Finally, more recently, Cazzola et al., looking at data from the Health Search Database of the Italian College of General Practitioners, reported that asthma was weakly associated with cardiovascular and hypertensive diseases;[10] surprisingly, the odds ratio of acute or past myocardial infarction was 0.84 (95% CI: 0.77–0.91). Furthermore, although asthma was weakly associated with depression, diabetes mellitus, dyslipidaemia, osteoporosis and rhinosinusitis, it was strongly associated with GERD and allergic rhinitis. There was no influence of age on the association of asthma with comorbidities.

    In this article, we will further describe the relationships between asthma and its main associated comorbid conditions, particularly those with a potential or established influence on asthma control.